Details for Patent: 8,999,996
✉ Email this page to a colleague
Which drugs does patent 8,999,996 protect, and when does it expire?
Patent 8,999,996 protects XPOVIO and is included in one NDA.
This patent has one hundred and two patent family members in thirty-seven countries.
Summary for Patent: 8,999,996
| Title: | Hydrazide containing nuclear transport modulators and uses thereof |
| Abstract: | The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity. |
| Inventor(s): | Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter |
| Assignee: | Karyopharm Therapeutics Inc |
| Application Number: | US14/219,638 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 8,999,996
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-005 | Mar 10, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-003 | Apr 15, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-004 | Apr 15, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,999,996
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2736887 | ⤷ Start Trial | 301119 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2736887 | ⤷ Start Trial | PA2021007 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2736887 | ⤷ Start Trial | CA 2021 00031 | Denmark | ⤷ Start Trial |
| European Patent Office | 2736887 | ⤷ Start Trial | LUC00219 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2736887 | ⤷ Start Trial | 2021C/532 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
